These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 10667585)

  • 1. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
    Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
    Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC; Sakamoto GT; Henderson DR
    Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
    Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
    Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
    Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
    Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
    Pang S; Dannull J; Kaboo R; Xie Y; Tso CL; Michel K; deKernion JB; Belldegrun AS
    Cancer Res; 1997 Feb; 57(3):495-9. PubMed ID: 9012480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
    Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
    Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
    Chapel-Fernandes S; Jordier F; Lauro F; Maitland N; Chiaroni J; de Micco P; Mannoni P; Bagnis C
    Cancer Gene Ther; 2006 Oct; 13(10):919-29. PubMed ID: 16741521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
    Suzuki S; Tadakuma T; Asano T; Hayakawa M
    Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
    Liu BH; Wang X; Ma YX; Wang S
    Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
    Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
    Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
    Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
    Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
    Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
    Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.